

EssilorLuxottica joins the Collaborative Community on Ophthalmic Innovation, strengthening global commitment to transforming eye health

Paris, France (13 November 2025) – EssilorLuxottica announces its membership in the Collaborative Community of Ophthalmic Innovation (CCOI), a global catalyst uniting patients, clinicians, researchers, regulators, and industry to accelerate breakthrough science into real-world solutions – unlocking the eye’s potential to advance both ophthalmology and the broader healthcare ecosystem.

Joining the CCOI highlights EssilorLuxottica’s long-standing commitment to patient-centric innovation across diagnostics, treatment and data-driven ophthalmology. Through multi-stakeholder collaboration, scientific rigor and consensus-building, the Group will contribute optical engineering excellence, digital health capabilities and global scale to help translate emerging science into meaningful patient outcomes.

“Joining the Community at the highest level of industry participation reflects our dedication to advancing ophthalmic science through industry collaboration. By integrating our capabilities with the Community’s collective knowledge, we aim to accelerate translational research and clinical breakthroughs that will redefine how eye diseases are detected, managed, and ultimately prevented. We are also proud to bring capabilities from across our Group, including Heidelberg Engineering, whose decades of leadership in imaging and data science will help drive the next generation of evidence-based ophthalmic innovation”, commented Dr. Norbert Gorny, Chief Scientific Officer at EssilorLuxottica.

“We are honored to welcome EssilorLuxottica as a Vision Architect of the Collaborative Community on Ophthalmic Innovation,” said Dr. Malvina Eydelman, CEO of CCOI. *“Through this leadership role, EssilorLuxottica will help shape global standards and scientific frameworks by driving CCOI’s Endpoints Consensus Workshops and global standards initiatives – advancing a unified, patient-centered foundation for ophthalmic innovation worldwide.”*

Aligned with its open and collaborative approach, the Group will engage in the CCOI’s key workstreams, including myopia, oculomics, AI, age-related macular degeneration and glaucoma, applying its scientific and technological strengths to advance global eye health.

Contacts

Giorgio Iannella
Head of Investor Relations
ir@essilorluxottica.com

Marco Catalani
Head of Corporate Communications
media@essilorluxottica.com

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. Its Mission is to help people around the world to see more and be more by addressing their evolving vision needs, personal style aspirations and desire to feel more connected to the world around them. EssilorLuxottica is home to the most innovative lens technologies, including Varilux, Stellex and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo. Backed by robust R&D investments, distinctive capabilities and a top-quality asset portfolio, the Company drives innovation across categories, from cutting-edge medical instruments and solutions for eye health to category-defining smart glasses, all of which push the boundaries of the industry and reimagine the eyes as a gateway to new possibilities. With over 200,000 employees across 150 countries, 600 operations facilities, serving 300,000 eye care professionals and operating 18,000 stores, the Group generated consolidated revenue of Euro 26.5 billion in 2024. Its OneSight EssilorLuxottica Foundation has given access to sustainable vision care to nearly 1 billion people in underserved communities. EssilorLuxottica trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP. www.essilorluxottica.com